Evergreening: How Drug Companies Stretch Patents to Block Generic Competition

When a drug company invents a new medicine, it gets 20 years of patent protection. That’s the rule. But in reality, many blockbuster drugs stay off-limits to generics for decades longer-sometimes over 30 years. How? Through a practice called evergreening. It’s not about inventing better drugs. It’s about inventing tiny changes to old ones-just enough to reset the patent clock.

What Evergreening Really Means

Evergreening isn’t a loophole. It’s a legal strategy, built into the system. After the 1984 Hatch-Waxman Act, the U.S. created a path for generic drugs to enter the market faster. But it also gave drug makers tools to delay them. Instead of letting a patent expire and letting cheaper versions take over, companies file new patents on minor tweaks: a slightly different pill coating, a new dosage form, a changed release schedule, or a combo with another drug already on the market.

These aren’t breakthroughs. They’re tweaks. A pill that releases medicine slower? That’s not a new cure. It’s a tweak. A pill that comes in a capsule instead of a tablet? Still the same active ingredient. But under patent law, these changes can qualify for a new 20-year clock. And sometimes, they get extra exclusivity too-like five years for a new use, or six months for pediatric studies.

The result? A single drug can have dozens of patents stacked on top of each other. AbbVie’s Humira, used to treat rheumatoid arthritis and Crohn’s disease, had 247 patent applications filed around it. Over 100 were granted. That’s not innovation. That’s a patent thicket-a wall of legal barriers designed to scare off generic makers who can’t afford to fight 100 lawsuits.

How It Works: The Playbook

Drug companies don’t wait until the last minute. They start planning five to seven years before the original patent expires. Teams of chemists, lawyers, and regulatory experts work together to find every possible angle to extend exclusivity.

• New formulation: Switching from a tablet to a liquid, or adding a time-release coating. AstraZeneca did this with Prilosec, turning it into Nexium-same active ingredient, but a new patent.
• New combination: Pairing an old drug with another drug that’s already off-patent. Suddenly, it’s a "new" product.
• Product hopping: Pulling the old version off the market and pushing patients to the new version. Patients are told the old one is "less safe" or "less effective," even when the difference is negligible.
• Authorized generics: The brand company itself launches a generic version at a lower price-just enough to keep real generics out. It looks like competition, but it’s still their product.
• Patenting genetic tests: If a drug works better for people with a certain gene, patent the test to identify them. Now, generics can’t even test patients without permission.

Each of these moves adds months or years. And when you stack them? You get decades. AstraZeneca extended market control on six drugs by over 90 years combined. That’s not a fluke. It’s standard business.

The Cost to Patients and the System

When a drug goes generic, prices drop by 80% to 85% within a year. That’s the power of competition. But evergreening blocks that. Patients keep paying $500, $1,000, or even $3,000 a month for drugs that could cost $50.

Humira alone brings in $40 million a day in revenue for AbbVie. That’s because, for over a decade, no generic could enter. Millions of Americans with autoimmune diseases had no choice. Many skipped doses. Some went without. The system was designed to reward innovation-not to lock in profits on old drugs.

And it’s not just Humira. Drugs for diabetes, acid reflux, high cholesterol-all have been through this. The same active ingredients. The same effects. But patients pay premium prices because the brand companies won’t let go.

It’s not just about money. It’s about access. In low- and middle-income countries, evergreening keeps life-saving drugs out of reach entirely. The World Health Organization has called it a barrier to global health equity.

Why It’s Not Innovation

Developing a truly new drug costs $2.6 billion and takes 10 to 15 years. It’s risky. Most fail. But evergreening? It costs a fraction of that. A chemist tweaks a molecule. A lawyer files a patent. A marketing team rebrands it. Done.

Harvard researchers found that 78% of new patents for prescription drugs are for existing drugs-not new ones. That means the system is being used to protect old money, not fund new science.

Real innovation should be rewarded. But when companies spend more on legal teams than on R&D, you’re not getting better medicine-you’re getting more expensive medicine.

Regulators Are Fighting Back

The system isn’t completely broken. There are signs of pushback.

In 2022, the U.S. Federal Trade Commission sued AbbVie over Humira’s patent strategy, calling it anticompetitive. The FTC argued that the 247 patents were a sham-a way to block competition without real innovation.

The Inflation Reduction Act of 2022 let Medicare negotiate prices for some of the most expensive drugs. That cuts the profit motive behind evergreening. If the government can cap prices, companies lose the incentive to stretch patents just to keep high prices.

The European Medicines Agency now requires proof of "significant clinical benefit" before granting extra exclusivity. That’s a big shift. It means you can’t just tweak a drug-you have to prove it’s better for patients.

And the U.S. Patent Office is getting stricter on "obvious" patents. If a change is too simple, too predictable, it’s being rejected.

What’s Next?

Drug companies aren’t giving up. They’re evolving.

Now, they’re moving into biologics-complex drugs made from living cells. These are harder to copy. Even if a patent expires, making an exact copy is nearly impossible. So companies are patenting delivery systems, storage methods, and even the way the drug is administered.

They’re also using pharmacogenomics-patenting genetic tests that determine who responds to the drug. That creates a new layer of control.

But the tide is turning. Public pressure is rising. More lawmakers are asking: Why should a company get 30 years of monopoly on a drug that’s been around for 15?

Patients aren’t asking for free medicine. They’re asking for fair competition. If a drug’s active ingredient is old, why shouldn’t it be cheap?

Final Thought: The System Was Designed to Balance Two Things

Patents exist to reward innovation. Generics exist to make medicine affordable. Evergreening breaks that balance. It turns a temporary monopoly into a permanent one.

The real question isn’t whether companies should protect their inventions. It’s whether they should be allowed to game the system to keep old drugs off the market. The answer, for many, is no.